No Data
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
PHARMARON (03759) received a portion of shares pledged and released by the actual controller, Lou Xiaoqiang, and Longtaikang.
PHARMARON (03759) announced that the company recently received a notification from one of its actual controllers, Mr. Lou Xiaoqiang, and his consensus...
PHARMARON (03759.HK) spent 7.2501 million Hong Kong dollars to repurchase 0.542 million shares on January 2.
Gelonghui, January 2丨PHARMARON (03759.HK) announced that on January 2, 2025, it spent 7.2501 million Hong Kong dollars to repurchase 0.542 million shares, with a repurchase price of 13.32-13.44 Hong Kong dollars per share.
Zhihui Tong Hong Kong Stock Repurchase Statistics | January 1.
Hong Kong Stock Repurchase Statistics | January 1
On December 30, PHARMARON (03759.HK) spent 6.1614 million HKD to repurchase 0.4405 million shares.
Gelonghui, December 30丨PHARMARON (03759.HK) announced that on December 30, 2024, it spent 6.1614 million Hong Kong dollars to repurchase 0.4405 million shares, with a repurchase price ranging from 13.94 to 14 Hong Kong dollars per share.
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
Expand
No Data
102884128 : getting disappointed with this counter. every day drop.